New WHO reagent for autoantibodies in SLE patients
A new study published in the journal Annals of the Rheumatic Diseases presents a WHO reference reagent produced by an international team of researchers and clinical laboratories. This reagent will facilitate the adjustment of autoantibody analyses in SLE and thereby also diagnosis and therapy for SLE patients.
Systemic lupus erythematosus (SLE) is a rheumatic disease that mainly afflicts women of childbearing age. For the diagnosis of SLE, antibodies against dsDNA is often used. In 1985, the World Health Organisation (WHO) produced a reference preparation for autoantibodies against dsDNA that has been used globally by hospital laboratories and companies that produce test methods for measuring autoantibodies against dsDNA.
The reference preparation ran out more than ten years ago and in the present article Johan Rönnelid at IGP together with his colleagues describe their work to produce and evaluate a new reference preparation. The new preparation has been approved by the WHO and the researchers expect that it will be used to standardise different methods for measuring autoantibodies against dsDNA, thereby improving diagnosis and treatment of patients with SLE.